Hanssen Pharmaceuticals (03692.HK): HS-10510 tablets received a drug clinical trial approval notice issued by the National Medical Products Administration.

Zhtng Cijng APP news, Hansun Pharmaceuticals (03692.HK) announced that the group's independently developed new drug HS-10510 tablets have received the drug clinical trial approval notification issued by the China National Medical Products Administration (NMPA), and are planned to be used for clinical trials for primary hypercholesterolemia and mixed dyslipidemia.